Curcumin Based Drug Delivery Systems for Cancer Therapy

Area of Science:

• Pharmacology and Toxicology
• Natural Product Chemistry
• Cancer Biology

Background:

• Cancer is a leading global cause of death, with conventional therapies facing challenges like toxicity, resistance, and recurrence.
• Curcumin (CUR), a polyphenol from Curcuma longa, exhibits significant anti-cancer and chemo-preventive properties by targeting cancer cell signaling pathways and modulating immune responses.
• Despite its potential, CUR's clinical application is limited by poor aqueous solubility, low bioavailability, rapid metabolism, and reduced cellular uptake.

Purpose of the Study:

• To review recent advancements in nanoformulations designed to overcome CUR's pharmacokinetic limitations for enhanced cancer therapy.
• To provide an overview of CUR's molecular targets in cancer treatment.
• To discuss the role of CUR in cancer immunotherapy.

Main Methods:

• Literature review focusing on nanoformulations of curcumin for cancer treatment.
• Analysis of molecular targets and signaling pathways affected by CUR.
• Exploration of CUR's impact on innate and adaptive immune systems in cancer contexts.

Main Results:

• Various nanoformulations including liposomes, polymeric nanoparticles, solid lipid nanoparticles, micelles, nanoemulsions, microspheres, and nanogels have been developed to improve CUR's bioavailability and efficacy.
• CUR demonstrates broad-spectrum anti-tumor activity through modulation of key cancer-related signaling cascades.
• CUR exhibits potential in cancer immunotherapy by interacting with immune system components.

Conclusions:

• Nanoformulations represent a promising strategy to enhance the therapeutic potential of curcumin in cancer treatment.
• Further research into CUR's molecular mechanisms and its integration into immunotherapeutic approaches is warranted.
• Curcumin, when effectively delivered via nanoformulations, holds promise for safer and more effective cancer chemoprevention and therapy.